At EIT Pharma, Inc., we believe no patients should be left behind. We are dedicated to providing the best resources to empower our patients.
Hepatitis D
Overview of Hepatitis D
Hepatitis D is caused by Hepatitis D Virus (HDV). About 12 million people globally have experienced HDV infection.1 In the US, there are about 70,000 to 150,000 patients.2 HDV infection requires HBV infection, and can cause liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), and even death.3 Additionally, HDV is associated with significantly increased economic burden regarding healthcare resources utilization and costs.4
Currently, there has been no FDA-approved therapy for Hepatitis D in the US. Per clinical guidelines, treatment options for Hepatitis D may include peg-IFN, nucleotide analogues, such as entecavir and tenofovir.5
Additional Resources for Patients:
- Hepatitis B Foundation: Home » Hepatitis B Foundation
- CDC Hepatitis D: Hepatitis D Basics | Hepatitis D | CDC
- AASLD 2018 Hepatitis B Guidance: Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance – PMC
References:
- Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020 Sep;73(3):523-532. doi: 10.1016/j.jhep.2020.04.008. Epub 2020 Apr 23. PMID: 32335166; PMCID: PMC7438974.
- Gish RG. Delta Hepatitis in the United States: Epidemiology, Testing, and Linkage to Care. Gastroenterol Hepatol (N Y). 2023 Oct;19(10):603-605. PMID: 38404959; PMCID: PMC10882855.
- Kamal H, Aleman S; D-SOLVE Consortium. Natural history of untreated HDV patients: Always a progressive disease? Liver Int. 2023 Aug;43 Suppl 1:5-21. doi: 10.1111/liv.15467. Epub 2022 Nov 11. PMID: 36308026.
- Maughn K, et al. 2022. Characteristics, Healthcare Resource Utilization and Costs Among Medicaid-Insured Adults With Hepatitis Delta Virus: An Analysis of US All-Payer Medical and Pharmacy Claims Data. Link.
- Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800. PMID: 29405329; PMCID: PMC5975958.
Acute Respiratory Infection
Overview of Acute Respiratory Infection
Acute Respiratory Infection (ARI) is a disease that interferes with normal breathing, which can be caused by a variety of infections such as viral and bacterial infection.1 ARI is associated with significantly increased morbidity and mortality and is a leading cause of death worldwide.2 It also results in considerable economic burden to patients and healthcare systems.3
Treatments for ARI are determined by identifying causes of infection. Antibiotic treatments and/or antiviral treatments may be used.
References:
- Cui C, Timbrook TT, Polacek C, Heins Z, Rosenthal NA. Disease burden and high-risk populations for complications in patients with acute respiratory infections: a scoping review. Front Med (Lausanne). 2024 May 16;11:1325236. doi: 10.3389/fmed.2024.1325236. PMID: 38818396; PMCID: PMC11138209.
- Mayor S. Acute respiratory infections are world’s third leading cause of death. BMJ. (2010) 341:c6360. doi: 10.1136/bmj.c6360
- Averin A, Sato R, Begier E, Gessner BD, Snow V, Cane A, Quinn E, Atwood M, Kijauskaite G, Weycker D. Annual public health and economic burden of medically attended respiratory syncytial virus illnesses among US adults. Vaccine. 2024 Dec 2;42(26):126323. doi: 10.1016/j.vaccine.2024.126323. Epub 2024 Sep 20. PMID: 39305838.
- CDC. Clinical Guidance for Patients with Acute Respiratory Illness Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co-Circulating. Link: Clinical Guidance for Patients with Acute Respiratory Illness Being Hospitalized When SARS-CoV-2 and Influenza Viruses are Co-Circulating | Influenza (Flu) | CDC
Early Access Program
EIT Pharma, Inc., believes the most effective and safest approach to provide access to investigational therapy for our patients is through participation in our ongoing clinical trials. Please find ongoing clinical trials sponsored by EIT Pharma, Inc., at https://clinicaltrials.gov/.
For more information about early access, please contact us: